pfizer says akzo nobel nv said unit organon pfizer inc agreed end collaboration development antipsychotic drug asenapine effect planned stock market flotation organon pfizer decision discontinue participation asenapine development program 'is outcome commercial analysis compound part overall portfolio companies said organon continue develop product regardless pfizer lack collaboration according clinicaltrials gov studies investigated drug currently recruiting patients looks like organon swinging bipolar schizophrenia however compound late game atypical market flooded i going boldly predict asenapine work better existing product going take whale marketing effort push one importance organon sake i hope get better market share asenapine mirtazapine remeron source